NCT04550260: An ongoing trial by AstraZeneca
This trial is ongoing. It must report results 1 year, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04550260 |
|---|---|
| Title | A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 19, 2020 |
| Completion date | Nov. 28, 2025 |
| Required reporting date | Nov. 28, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 28, 2025 |
| Days late | None |